Logo do repositório
 
Publicação

Off-label prescribing : scientific analysis taking the use of bevacizumab in ophthalmology as an example

2013Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorAlarcão, Joana
dc.contributor.authorCosta, João
dc.contributor.authorFareleira, Filipa
dc.contributor.authorBorges, Margarida
dc.contributor.authorCarneiro, António Vaz
dc.date.accessioned2018-03-05T14:49:18Z
dc.date.available2018-03-05T14:49:18Z
dc.date.issued2013
dc.description.abstractOff-label prescribing poses specific technical/scientific, professional and ethical problems. In this study we carry out a technical and scientific analysis of the off-label prescribing using a current, clinical and economically relevant example: the paradigmatic case of the use of bevacizumab in ophthalmologic pathologies for which it has no formal indication. We conducted a systematic review of the literature on the efficacy and safety of this drug, as well as ranibizumab - which has approved ophthalmologic indications, in order to qualitatively analyze the available evidence on the two interventions. This is a typical case for technical and scientific analysis of the off-label prescribing problems. According to the results of the systematic review, the use of bevacizumab in this context has in fact scientific evidence of appreciable size, including clinical trials head-to-head with ranibizumab. However, the identified safety issues raise the question of the use of this drug in ophthalmologic pathologies. The different players involved in the treatment decisions (physicians, patients and institutional decision makers) should be adequately informed about the existing evidence that supports off-label prescribing which, by definition, must always be on an exceptional basis and properly justified.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationActa Med Port 2013 Jul-Aug;26(4):409-419pt_PT
dc.identifier.issn1646-0758
dc.identifier.urihttp://hdl.handle.net/10451/32127
dc.language.isoporpt_PT
dc.peerreviewedyespt_PT
dc.publisherActa Médica Portuguesapt_PT
dc.relation.publisherversionhttps://www.actamedicaportuguesa.com/pt_PT
dc.subjectAntibodies, monoclonal, humanizedpt_PT
dc.subjectBevacizumabpt_PT
dc.subjectMacular degenerationpt_PT
dc.subjectMacular edemapt_PT
dc.subjectRetinal vein occlusionpt_PT
dc.subjectRanibizumabpt_PT
dc.subjectOff-label usept_PT
dc.titleOff-label prescribing : scientific analysis taking the use of bevacizumab in ophthalmology as an examplept_PT
dc.title.alternativePrescrição off-label : análise científica tendo como exemplo a utilização de Bevacizumab em oftalmologiapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage419pt_PT
oaire.citation.issue4pt_PT
oaire.citation.startPage409pt_PT
oaire.citation.titleActa Médica Portuguesapt_PT
oaire.citation.volume26pt_PT
person.familyNameCosta
person.familyNameBorges
person.familyNameVaz Carneiro
person.givenNameJoão
person.givenNameMargarida
person.givenNameAntónio
person.identifier480560
person.identifier.orcid0000-0002-5831-4921
person.identifier.orcid0000-0002-8563-6846
person.identifier.orcid0000-0002-2783-0544
person.identifier.ridL-8026-2013
person.identifier.scopus-author-id55499748300
person.identifier.scopus-author-id7102828573
person.identifier.scopus-author-id7006837792
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication0924f405-2d3a-4914-9097-24aa639bd97f
relation.isAuthorOfPublicationa414c62c-f8d0-447e-b0bc-779588853440
relation.isAuthorOfPublication376d157f-1127-4663-9d99-038dac28f37d
relation.isAuthorOfPublication.latestForDiscovery0924f405-2d3a-4914-9097-24aa639bd97f

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Prescricao_off_label.pdf
Tamanho:
324.47 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-CEMBE-Artigos em Revistas Nacionais